The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.
 
Antoine Adenis
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Bristol-Myers Squibb; Merck; Merck Serono
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology
Research Funding - Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; SERVIER
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Ludovic Gauthier
No Relationships to Disclose
 
Thibault Mazard
Consulting or Advisory Role - AAA HealthCare; Amgen; Merck Serono; Pierre Fabre; Pierre Fabre; Sandoz; SERVIER
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Pierre Fabre
 
Ludovic Evesque
No Relationships to Disclose
 
Pierre-Luc Etienne
Travel, Accommodations, Expenses - BMSi; SERVIER
 
Alexandre Evrard
No Relationships to Disclose
 
Patrick Chalbos
Research Funding - Bayer
 
Jean-Pierre Bleuse
No Relationships to Disclose
 
Diego Tosi
Consulting or Advisory Role - Actelion (I); Biomarin (I); Brenus Pharma
Research Funding - Astellas Pharma; Bayer; Ipsen; Janssen
Patents, Royalties, Other Intellectual Property - I have a pending patent on a new drug combination for prostate cancer treatment
Travel, Accommodations, Expenses - Amicus Therapeutics (I); AstraZeneca; AstraZeneca; Biomarin (I); Ipsen; Janssen; Janssen; MSD; Nutricia (I); Pfizer
 
Sophie Gourgou
Consulting or Advisory Role - Celgene; Roche
 
Marc Ychou
Honoraria - Bayer